Hematology & Medical Oncology

Quick Links

* (IM Hematology Profile)

Damian Laber

Damian Laber, MD, FACP

Professor and Director, Hematology/Oncology

Contact Info

Education

  • MD, Medicine, Colegio Nacional De Buenos Aires*, 1986

Interdisciplinary and Emerging Signature Programs

  • Other

Research Interests

  • Dr. Laber's research interests have been devoted to translational research with special interest in hematology, genitourinary malignancies, gastrointestinal malignancies and early clinical trials of new therapies. He has been the principal investigator in multiple clinical trials that had led to the development and approval of novel therapies for several cancers including prostate, kidney, colon, breast, lung, myeloproliferative disorders and many other malignancies. Dr. Laber's other areas of research interest include heparin-induced thrombocytopenia, thrombosis in cancer, venous thromboembolism, coagulation and bleeding disorders.
  • Dr. Laber has published in prestigious scientific journals such as The New England Journal of Medicine, Journal of Clinical Oncology, Blood, Cancer Investigation, American Journal of Hematology and European Journal of Haematology.

Awards/Honors

  • Best Teaching Faculty (University of Louisville, JG Brown Cancer Center - 2003)

Memberships

  • Member (European Society of Hematology, 2006 - Present)
  • Member (American Society of Hematology, 1997 - Present)
  • Member (American Society of Clinical Oncology, 1997 - Present)
  • Fellow (American College of Physicians, 1994 - Present)

Recent Publications

  • Laber DA, Khan MI, Kloecker GH, Schonard C, Taft BS, Salvador C. A phase I study of thalidomide, capecitabine and temozolomide in advanced cancer. Cancer biology & therapy. 6(6) : 840-5, 2007.
  • Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. American journal of hematology. 82(10) : 916-9, 2007.
  • Choudry MA, Moffett BK, Laber DA. Pure red-cell aplasia secondary to pregnancy, characterization of a syndrome. Annals of hematology. 86(4) : 233-7, 2007.
  • Laber DA. Risk factors, classification, and staging of renal cell cancer. Medical oncology (Northwood, London, England). 23(4) : 443-54, 2006.
  • Visweshwar N Malachowski S Patel A Jaglal M Laber D. Accidental and surreptitious intake of oral anticoagulants including older and newer agents –A diagnostic dilemma. J Hematol Thromb. 3(1) : 3, 2017.
  • Sandoval-Sus JD, Mogollon-Duffo F, Patel A, Visweshwar N, Laber DA, Kim R, Jagal MV. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. Journal for immunotherapy of cancer. 5: 49, 2017.
  • Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M. Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfusion medicine (Oxford, England). 27(4) : 300-302, 2017.
  • Visweshwar N Malachowski S Jaglal M Laber D. Is warfarin obsolete? SM J Oncol Hematol.. 1(1) : 1002, 2016.
  • Jaglal MV, Laber DA, Arnold FW, Miller DM, Chesney JA, Kloecker GH. Obtaining routine blood cultures during interleukin-2-containing therapy is unnecessary. American journal of clinical oncology. 32(4) : 429-31, 2009.
  • Visweshwar N Jaglal M Booth C Griffin P Laber D. Paroxysmal nocturnal hemoglobinuria with autoimmune hemolytic anemia following eculizumab therapy-with large granular lymphocytic leukemia. Ann Hematol.. 95(10) : 1747-9., 2016.
  • Khan MI, Chesney JA, Laber DA, Miller DM. Digitalis, a targeted therapy for cancer? The American journal of the medical sciences. 337(5) : 355-9, 2009.
  • Molander L Caraway C Linderbeck L Laber DA. Cerebrospinal Fluid (CSF) Directed Antineoplastic Agents: A Review of Current Knowledge. J Cancer Prev Curr Res. 2(2) : 00026. DOI: 10.15406/jcpcr.2015.02.00026, 2015.
  • Harandi A, Zaidi AS, Stocker AM, Laber DA. Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers. Journal of oncology. 2009: 567486, 2009.
  • Rosenberg JE, Bambury RM, Van Allen EM, Drabkin HA, Lara PN, Harzstark AL, Wagle N, Figlin RA, Smith GW, Garraway LA, Choueiri T, Erlandsson F, Laber DA. A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Investigational new drugs. 32(1) : 178-87, 2014.
  • Kloecker GH, Kannan CR, Laber DA, Rezazadeh A. Brain stem and clivus plasmacytoma. The American journal of the medical sciences. 336(6) : 503, 2008.
  • Zhang W, Rabinowits G, Laber DA, Kloecker GH. Effect of zoledronic acid on tartrate-resistant acid phosphatase isoform type 5b and other bone markers in lung cancer patients with bone metastases Pathology and Laboratory Medicine International. 4: 5-11, 2012.
  • Slone SP, Martin AW, Wellhausen SR, Woods DR, Malone JC, Lear SC, Laber DA. IL-4 production by CD8+ lymphomatoid papulosis, type C, attracts background eosinophils. Journal of cutaneous pathology. 35 Suppl 1: 38-45, 2008.
  • Storey RE, Huerta AL, Khan A, Laber DA. Spontaneous complete regression of hepatocellular carcinoma. Medical oncology (Northwood, London, England). 28(4) : 948-50, 2011.
  • Martin ME, Kloecker GH, Laber DA. Argatroban for anticoagulation during cardiac surgery. European journal of haematology. 78(2) : 161-6, 2007.
  • Rabinowits G, Bhupalam L, Miller DM, Kloecker GH, Laber DA. Fixed-dose every-other-week capecitabine and oxaliplatin for refractory squamous cell carcinoma of the head and neck. The American journal of the medical sciences. 339(2) : 148-51, 2010.
  • Rabinowits G, Shuster TD, Pazianos AG, Laber DA. Indolent course of thymic carcinoid. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(9) : 1138-9, 2007.
  • Rabinowits G, Laber DA. Bladder cancer: clinical practice. The Journal of the Kentucky Medical Association. 107(4) : 129-33, 2009.
  • Kloecker GH, Studts JL, Laber DA, Bousamra M. Lung cancer in the US and in Kentucky. The Journal of the Kentucky Medical Association. 105(4) : 159-64, 2007.
  • Laber DA, Mushtaq M. Compassionate use of sorafenib in patients with advanced renal cell cancer. Clinical genitourinary cancer. 7(1) : 34-8, 2009.
  • Moffett PU, Moffett BK, Laber DA. Diagnosing and managing suspected malignant pleural effusions. The journal of supportive oncology. 7(4) : 143-6, 2009.
  • Rezazadeh A, Laber DA, Ghim SJ, Jenson AB, Kloecker G. The role of human papilloma virus in lung cancer: a review of the evidence. The American journal of the medical sciences. 338(1) : 64-7, 2009.
  • Bates PJ, Laber DA, Miller DM, Thomas SD, Trent JO. Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Experimental and molecular pathology. 86(3) : 151-64, 2009.

Positions Held

  • Professor and Director (OU Tulsa Cancer Center, University of Oklahoma 2010 - 2012)
  • Gussman Char and Chief (Hematology/Oncology, University of Oklahoma 2010 - 2012)
  • Director Fellowship Program (Hematology/Oncology, University of Louisville 2001 - 2010)
  • Director Genitourinary Cancer Research (JG Brown Cancer Center, University of Louisville 2001 - 2010)